Neuromodulation for Apathy in Alzheimer's Disease: A Double-Blind, Randomized, Sham-Controlled Pilot Study - PubMed (original) (raw)
Randomized Controlled Trial
Neuromodulation for Apathy in Alzheimer's Disease: A Double-Blind, Randomized, Sham-Controlled Pilot Study
Prasad R Padala et al. J Alzheimers Dis. 2020.
Abstract
Background: Apathy, a profound loss of motivation, initiation, and goal directed cognition, is a common comorbidity of Alzheimer's disease (AD). The presence of apathy is associated with rapid progression of AD, long-term impairment, disability, and higher mortality. Pharmacological treatments of apathy are limited.
Objective: The primary objective was to evaluate the efficacy of repetitive transcranial magnetic stimulation (rTMS) for apathy in AD.
Methods: A randomized, double-blind, parallel-arm, sham-controlled pilot study was conducted in subjects with AD and apathy (N = 20). Subjects were randomized to rTMS or sham treatment (5 days/week) for four weeks. Primary outcome, apathy evaluation scale-clinician version (AES-C), and secondary outcome measures, modified-Mini Mental State Examination (3MS), instrumental activities of daily living (IADL), and clinical global impression (CGI), were assessed at baseline and four weeks. Follow-up visits were conducted at 8 and 12 weeks to test the durability of effects of intervention.
Results: Mean age was 77.3 (±7.2) years, 80% were Caucasians and 10% were females. After adjusting for baseline, there was a significantly greater improvement in the AES-C with rTMS compared to sham treatment (-10.1 (-15.9 to -4.3); t (16) = -3.69; p = 0.002) at 4 weeks. There was also significantly greater improvement in 3MS (6.9 (1.7 to 12.0); t (15) = 2.85; p = 0.012), IADL (3.4 (1.0 to 5.9); χ21 = 7.72; p = 0.006), CGI-S (1.4 (0.5 to 2.3), t (16) = 3.29; p = 0.005), and CGI-I (-2.56 (-3.5 to -1.6), t (17) = -5.72; p < 0.001) for rTMS compared to the sham at 4 weeks. The effects of rTMS were durable at 12 weeks.
Conclusion: rTMS may be safely used in subjects with AD and may improve apathy, function, and some aspects of cognition.
Trial registration: ClinicalTrials.gov NCT02190084.
Keywords: Alzheimer’s disease; apathy; behavioral problems in dementia; repetitive transcranial magnetic stimulation.
Conflict of interest statement
Authors’ disclosures available online (https://www.j-alz.com/manuscript-disclosures/20-0640r2).
Figures
Fig. 1
Screening, Enrollment, and Participation aReason for exclusion: 1-substance abuse, 3-travel, 6-not interested, 4-time, 4-bipolar disorder, 4-did not meet criteria for AD, 3-h/o head trauma, 1-contraindicated medication (bupropion), 1-implants, 1-another study, 2-younger age, 2-h/o stroke, 1-deteriorating caregiver health.
References
- Ishii S, Weintraub N, Mervis JR (2009) Apathy: A common psychiatric syndrome in the elderly. J Am Med Dir Assoc 10, 381–393. -PubMed
- Robert P, Onyike CU, Leentjens AF, Dujardin K, Aalten P, Starkstein S, Verhey FR, Yessavage J, Clement JP, Drapier D, Bayle F, Benoit M, Boyer P, Lorca PM, Thibaut F, Gauthier S, Grossberg G, Vellas B, Byrne J (2009) Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. Eur Psychiatry 24, 98–104. -PubMed
- Holthoff VA, Beuthien-Baumann B, Kalbe E, Lüdecke S, Lenz O, Zündorf G, Spirling S, Schierz K, Winiecki P, Sorbi S, Herholz K (2005) Regional cerebral metabolism in early Alzheimer’s disease with clinically significant apathy or depression. Biol Psychiatry 57, 412–421. -PubMed
- Starkstein SE, Mizrahi R, Capizzano AA, Acion L, Brockman S, Power BD (2009) Neuroimaging correlates of apathy and depression in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 21, 259–265. -PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical